Announcement • Jun 17
Gland Pharma Limited and Gland Pharma International Pte. Ltd. Announces Management Changes, Effective June 15, 2026
Gland Pharma Limited held a board meeting on June 15, 2026. The board appointed Mr. William Robert Keller (DIN: 11593622), currently an Independent Director on the Board of Wuxi Biologics Limited, as an Additional Director (Non-Executive - Independent Director) of the Company with effect from June 15, 2026. Mr. William Robert Keller, aged 78, is currently an Independent Director of Wuxi Biologics, a global Contract Research, Development and Manufacturing Organization (CRDMO) in Biologics, listed on Hongkong Stock Exchange. He is also an Independent Director on Hua Medicine, a Company listed on Hongkong Stock Exchange. During August, 2020 to August, 2025; Mr. William Keller was a Director of Cathay Biotech Inc, which is listed on Shanghai Stock exchange. He was the Chairman of Coland Pharmaceutical Co. Ltd. (earlier listed on Taiwan Stock Exchange) for ten years till November, 2020. Earlier, from December, 2009 to May, 2015; he was an Independent Director on the Board of Alexion Pharmaceuticals Inc., a Nasdaq listed entity. For seven years, till December, 2014 Mr. William Keller was also an Independent Director of Taigen Biopharmaceutical Holding Limited, a Taiwan Stock Exchange listed company. Mr. William Keller has more than 40 years of experience in managing operations in South America and Asia, particularly in pharmaceutical and biotechnology sectors. Mr. Keller spent almost three decades in different management positions with Roche in South America and Asia. From 1990 to 1994, he served as the Managing Director of Roche Hong Kong with regional responsibilities, and subsequently from 1994 to 2003, he was the General Manager for Roche China Holding, and Shanghai Roche Pharmaceutical Ltd., where he established and built up the Roche business in China. In 2003, Mr. Keller founded Keller Pharma Consultancy, a pharmaceutical consulting firm focusing on market entry strategies for foreign biotech companies into the Chinese market and supporting biopharma start-up companies in Shanghai. During June, 1997 to December, 2013; Mr. Keller served as the Vice Chairman of the Shanghai Association of Enterprises with Foreign Investment, advising and supporting foreign invested companies as a business advisor. From March, 2003 to June, 2014; Mr. Keller was appointed as Deputy General Manager of Shanghai Zhangjiang Biotech and Pharmaceutical Base Development Co. Ltd, focusing on pharmaceutical and biotechnological industry development. From March, 2003 to December, 2013, he served as a Senior Consultant of the Shanghai Foreign Investment Development Board, providing advice regarding foreign investment development. From May, 2007 to April, 2010; Mr. Keller served as the Chairman of HBM Biomed China Partners Ltd., overseeing investments in biotechnology companies. Mr. Keller holds a Bachelor of Science degree from the School of Economics and Business Administration in Zurich, Switzerland, in July, 1972. Mr. Satyanarayana Murthy Chavali, Independent Director of the Company, tendered his resignation as an Independent Director in the Company due to the possibility of a potential conflict of interest that may arise in the future. The Company of which Mr. Satyanarayana Murthy is a Promoter and Director proposes entering a business segment that may be similar to or overlap with the business activities that Gland Pharma Limited is contemplating entering in the future. The resignation was accepted with effect from the close of the business hours on June 15, 2026. Mr. C.S.N. Murthy has been associated with the Company since November 20, 2018. Mr. Essaji Goolam Vahanvati, Independent Director of the Company, has been appointed as a Director on the Board of Gland Pharma International Pte. Ltd. (Material Subsidiary of the Company) with effect from June 15, 2026. The list of the Board of Directors of Gland Pharma International Pte. Ltd. after reconstitution is: Mr. Srinivas Sadu, Mr. Essaji Goolam Vahanvati, Mr. Wu Rong (Mr. Raymond Wu), Ms. Liao Rong (Ms. Carol Rong). The Committees of the Board have been realigned with effect from June 15, 2026. Audit Committee: Essaji Goolam Vahanvati - Chairman & Independent Director, William Robert Keller- Independent Director, Udo Johannes Vetter- Independent Director. Mr. William Keller was appointed as a member, replacing Mr. C.S.N. Murthy. Mr. Essaji Vahanvati has been appointed as the Chairman of the Committee. Nomination & Remuneration Committee: Udo Johannes Vetter - Chairman & Independent Director, Essaji Goolam Vahanvati- Independent Director, William Robert Keller- Independent Director, Ms. Wei Huang – Non-Executive Director. Mr. William Keller was appointed as a member, replacing Mr. C.S.N. Murthy. Mr. Udo J Vetter has been appointed as the Chairman of the Committee. Risk Management Committee: Naina Lal Kidwai- Chairperson & Independent Director, Srinivas Sadu- Executive Chairman, Dr. Jia Ai Zhang - Non- Executive Director, Ravi Shekhar Mitra- Chief Financial Officer. Stakeholders’ Relationship Committee & Share Transfer Committee: Udo J Vetter - Chairman & Independent Director, Srinivas Sadu- Executive Chairman & CEO, Wenjie Zhang- Non- Executive Director. Mr. Udo J Vetter was appointed as the Chairman of the Committee replacing Mr. C.S.N. Murthy. Corporate Social Responsibility Committee: Srinivas Sadu- Chairman & Executive Chairman, Essaji Goolam Vahanvati- Independent Director, Dr. Jia Ai Zhang- Non-Executive Director. ESOP Compensation Committee: Udo J Vetter- Chairman & Independent Director, Essaji Goolam Vahanvati- Independent Director, Srinivas Sadu- Executive Chairman. Mr. Srinivas Sadu was appointed as a member, replacing Mr. C.S.N. Murthy. Mr. Udo J Vetter has been appointed as the Chairman of the Committee.
